Symic Bio initiates SB-030 Phase 1/2a study in peripheral artery disease
Symic Bio, a California based biopharma focued on matrix biology, is all set to begin the phase 1/2a clinical study named as SHIELD of its peripheral artery disease drug, SB-030.
Symic Bio, a biopharmaceutical company based in California specializing in matrix biology, is set to commence a phase 1/2a clinical study, dubbed SHIELD, for its peripheral artery disease drug, SB-030. The study is scheduled across multiple sites in Australia and New Zealand, enlisting 67 patients with symptomatic peripheral artery disease. Trial Focus and Methodology SHIELD […]